Evidence map›Paper›PMID 30669147›Full record

ArticleAmerican journal of nephrology2019

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.

Tae-Hwi Schwantes-An, Sai Liu, Margaret Stedman, Brian S Decker, Leah Wetherill, Howard J Edenberg, Matteo Vatta, Tatiana M Foroud, Glenn M Chertow, Sharon M Moe

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tae-Hwi Schwantes-AnDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sai LiuDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Margaret StedmanDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Brian S DeckerDivision of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Leah WetherillDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Howard J EdenbergDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Matteo VattaDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Tatiana M ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Glenn M ChertowDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Sharon M MoeDivision of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA, smoe@iu.edu.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicineStanford University · US

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Genetic risks for cardiovascular events in ESRD patients from the EVOLVE study.R01DK100306 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M · 2014 to 2016
$1.0M
NCATS NIH HHS UL1 TR002529NIDDK NIH HHS R01 DK100306
6 · The paper itself

Abstract

backgroundElevated serum concentrations of fibroblast growth factor 23 (FGF23) are associated with cardiovascular mortality in patients with chronic kidney disease and those undergoing dialysis.

objectivesWe tested the hypotheses that polymorphisms in FGF23, its co-receptor alpha-klotho (KL), and/or FGF23 receptors (FGFR) are associated with cardiovascular events and/or mortality.

methodsWe used 1,494 DNA samples collected at baseline from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial, in which patients were randomized to the calcimimetic cinacalcet or placebo for the treatment of secondary hyperparathyroidism. We analyzed European and African Ancestry samples separately and then combined summary statistics to perform a meta-analysis. We evaluated single-nucleotide polymorphisms (SNPs) in FGF23, KL, and FGFR4 as the key exposures of interest in proportional hazards (Cox) regression models using adjudicated endpoints (all-cause and cardiovascular mortality, sudden cardiac death, and heart failure [HF]) as the outcomes of interest.

resultsrs11063112 in FGF23 was associated with cardiovascular mortality (risk allele = A, hazard ratio [HR] 1.32, meta-p value = 0.004) and HF (HR 1.40, meta-p value = 0.007). No statistically significant associations were observed between FGF23 rs13312789 and SNPs in FGFR4 or KL genes and the outcomes of interest.

conclusionsrs11063112 was associated with HF and cardiovascular mortality in patients receiving dialysis with moderate to severe secondary hyperparathyroidism.

Indexed as

AdultAgedCalcimimetic AgentsChronic Kidney Disease-Mineral and Bone DisorderCinacalcetDeath, Sudden, CardiacFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Predisposition to DiseaseGlucuronidaseHeart FailureHumansHyperparathyroidism, SecondaryKaplan-Meier EstimateKlotho ProteinsCalcimimetic AgentsCinacalcetFGF23 protein, humanFGFR4 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsReceptor, Fibroblast Growth Factor, Type 4Cardiovascular diseaseChronic kidney disease-mineral bone disorderDialysisFibroblast growth factor-23Mortality

Identifiers

PMID30669147
PMCPMC6473180
OpenAlexW2912093599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.